Imatinib 400mg tab Imalek

Trade Name: Imalek

Manufacturer: Sun Pharmaceutical Industries Ltd

Presentation: Tablet

Strength: 400mg

What is the purpose of the Imatinib 400mg tab?

Imatinib 400mg tab mesylate is licenced to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults and children. It’s used in adults to treat recurrent (comeback) or refractory illness (does not respond to treatment).

Is Imalek safe to take for a long time?

Although the optimal treatment period is uncertain, imatinib should normally be continued for 6–9 months, after which additional tumour shrinking is usually minimal.

Imatinib is a type of medication?

Imatinib is a tyrosine kinase inhibitor, which is a sort of cancer growth inhibitor (TKI). Tyrosine kinases are proteins that allow cells to communicate with one another in order to proliferate. Chemical messengers are what they do. There are several types of tyrosine kinases, and inhibiting them prevents cancer cells from developing.

What are the imatinib side effects?

  • Nausea/vomiting
  • diarrhoea
  • headache
  • muscular/joint discomfort
  • muscle cramps
  • dizziness
  • blurred vision
  • drowsiness are all possible side effects. If any of these adverse effects persist or worsen, contact your doctor or pharmacist right away. This medicine may cause major negative effects in those who take it. to see more click here 

Is imatinib a sleep aid?

Imatinib and other tyrosine kinase inhibitors (TKIs) for CML had to be taken every day for the rest of one’s life until recently, and the medications might cause exhaustion, depression, disrupted sleep, diarrhoea, and other side effects.

Is it possible to drink when taking imatinib?

For the course of your therapy, avoid grapefruit and grapefruit juice because they may interact with imatinib. Alcohol consumption (in tiny doses) appears to have no effect on the safety or effectiveness of imatinib.

What is the efficacy of imatinib?

The overall survival rate in the imatinib group was projected to be 83.3 per cent after ten years. Approximately half of the patients (48.3%) who were randomly assigned to imatinib completed the study, with 82.8 per cent having a full cytogenetic response

Is it possible that imatinib will harm your kidneys?

Imatinib therapy is linked to potentially irreversible acute renal injury in nonclinical trial CML patients, and long-term treatment may result in a clinically meaningful drop in estimated GFR.

if you are looking for another brand or product click on emfib